Preferred Partner Agreement
Cathal Friel, Chief Executive Officer of Open Orphan (LON:ORPH) Update
Open Orphan PLC (LON:ORPH) Maurice Treacy, Chief Commercial Officer Interview
Open Orphan signs agreement with Empiric Logic
Mereo BioPharma Grp (NASDAQ:MREO,LON:MPH) FDA Fast Track Designation for Navicixizumab
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S. Food
Tiziana Life Sci PLC (LON:TILS) Phase 2a Clinical Data
Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
Integumen PLC (LON:SKIN) Highlands Nat. Resources agreement with Cellulac
Integumen notes Highlands agreement with Cellulac plc to supply hemp-derived CBD for medical-grade conversion Integumen to use Cellulac converted CBD for Its skincare and Wound pHase wound care products
Tiziana Life Sci PLC (NASDAQ:TLSA LON:TILS) Dr Kunwar Shailubhai, CEO & CSO
Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma.
Midatech Pharma PLC (LON:MTPH) MTX102 Safety Results
Midatech Announces Safety Results from First in Human Study for Injectable MidaCore® Gold NanoParticle Diabetes Vaccine Programme – MTX102
FastForward Inn Ltd (LON:FFWD) Disposal of interest in Intensity Therapeutics Inc
FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast-growing and industry-leading businesses, is pleased to announce that it has completed the sale of its entire holding
Redx Pharma plc (LON:REDX) Sale of pan-RAF inhibitor programme
Redx to receive $3.5 million upfront, up to $203 million in milestone payments and royalty payments
Turner Pope Investments (TPI) latest research note on Integumen Plc (LON:SKIN)
As a function of the restructuring of the company since the end of 2018, Integumen has delivered a nine fold increase in revenue in H1 2019.
OKYO Pharma (LON:OKYO) Raj Patil, Director of Research & Development Podcast
Dr. Raj Patil is Sr. Director of Research & Development at OKYO Pharma speaks to Zak Mir. Dr. Patil brings more than 25 years of academic and pharmaceutical experience in
